Louisiana State Employees Retirement System Takes Position in Insulet Co. (NASDAQ:PODD)

Louisiana State Employees Retirement System bought a new stake in shares of Insulet Co. (NASDAQ:PODD) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,200 shares of the medical instruments supplier’s stock, valued at approximately $911,000.

Other large investors have also recently made changes to their positions in the company. Wolff Wiese Magana LLC boosted its stake in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares during the period. Parkside Financial Bank & Trust boosted its stake in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 123 shares during the period. Allworth Financial LP boosted its stake in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares during the period. BluePath Capital Management LLC purchased a new stake in shares of Insulet during the third quarter valued at $31,000. Finally, Turtle Creek Wealth Advisors LLC bought a new stake in shares of Insulet in the fourth quarter valued at about $43,000.

Insider Activity

In related news, Director Shacey Petrovic sold 11,609 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now owns 2,567 shares in the company, valued at $418,215.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 0.90% of the company’s stock.

Insulet Stock Performance

PODD opened at $164.17 on Friday. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The company has a market cap of $11.50 billion, a P/E ratio of 56.42, a price-to-earnings-growth ratio of 3.01 and a beta of 0.98. The firm’s 50-day moving average price is $172.00 and its 200-day moving average price is $179.25.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The firm had revenue of $509.80 million for the quarter, compared to the consensus estimate of $461.26 million. During the same quarter in the prior year, the company posted $0.55 earnings per share. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year. As a group, equities analysts anticipate that Insulet Co. will post 3.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Stifel Nicolaus lifted their price objective on Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. JPMorgan Chase & Co. lifted their price objective on Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. Piper Sandler decreased their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Finally, Barclays decreased their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.